Lydian

Lydian is a biotechnology company focused on revolutionizing the production of RNA-based medicines through its proprietary cell-free enzymatic synthesis platform. By moving away from traditional chemical and cell-based manufacturing, Lydian aims to produce high-purity mRNA, circular RNA, and self-amplifying RNA at scale with greater speed and lower costs. The company's technology is designed to overcome current bottlenecks in RNA manufacturing, enabling the development of more complex and effective genetic medicines. Lydian is positioned as both a platform provider and an internal drug developer, targeting a wide range of therapeutic areas including vaccines, oncology, and rare diseases.